Start Time: 16:30 January 1, 0000 4:59 PM ET

Dynavax Technologies Corporation (NASDAQ:DVAX)

Q3 2023 Earnings Conference Call

November 02, 2023, 16:30 PM ET

Company Participants

Ryan Spencer - CEO

Donn Casale - Chief Commercial Officer

Rob Janssen - Chief Medical Officer

Kelly MacDonald - CFO

Paul Cox - VP of IR and Corporate Communications

Conference Call Participants

Matthew Phipps - William Blair

Ernesto Rodriguez-Dumont - TD Cowen

Jonathan Miller - Evercore ISI

Roy Buchanan - JMP Securities

Operator

Good day, ladies and gentlemen, and welcome to Dynavax Technologies' Third Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's prepared remarks, we will open the call for questions and provide specific participation instructions at that time.

I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin.

Paul Cox

Thanks you all for participating in today's call. Joining me today from Dynavax are Ryan Spencer, Chief Executive Officer; Donn Casale, Chief Commercial Officer; Rob Janssen, Chief Medical Officer; and Kelly MacDonald, Chief Financial Officer.

Earlier today, Dynavax released financial results for the third quarter ended September 30, 2023. Copies of the press release and a supplementary slide presentation are available on Dynavax's Web site.

Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including but not limited to, potential market sizes, market segmentation, effective marketing efforts, future expected market share and related growth rates and related ACIP recommendation impacts on each, financial guidance and trends including revenue, profitability, cash flow, and sufficiency of current capitalization, timing and results of FDA submissions, clinical trial starts and data readouts and potential future uses or demand for our CpG 1018 adjuvant. These statements involve risks and uncertainties and our actual results may differ materially.

These risks are summarized in today's press release and detailed in the risk factors section of our SEC filings, including today's quarterly report on Form 10-Q. Our forward-looking statements speak as of today, and we undertake no obligation to update such statements.

And with that, I will now turn the call over to Ryan.

Ryan Spencer

Thanks, Paul. Good afternoon everyone and thank you for taking the time to join us to review Dynavax's results for the third quarter of 2023. We're pleased to report yet another record quarter of HEPLISAV-B revenue as we progress toward our goal of establishing HEPLISAV-B as the leading adult hepatitis B vaccine in the U.S. and market opportunity, which we believe will continue to expand to over $800 million by 2027.